Biotron Limited (ASX:BIT)

Australia flag Australia · Delayed Price · Currency is AUD
0.0030
0.00 (0.00%)
Mar 10, 2026, 11:11 AM AEST
-25.00%
Market Cap 8.11M
Revenue (ttm) -868.00
Net Income (ttm) -1.94M
Shares Out 2.70B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,404
Average Volume 3,050,521
Open 0.0030
Previous Close 0.0030
Day's Range 0.0030 - 0.0030
52-Week Range 0.0020 - 0.0050
Beta -0.83
RSI 48.39
Earnings Date Feb 23, 2026

About Biotron

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 3
Stock Exchange Australian Securities Exchange
Ticker Symbol BIT
Full Company Profile

Financial Performance

In fiscal year 2025, Biotron's revenue was 1.81 million, an increase of 10.24% compared to the previous year's 1.65 million. Losses were -318,572, -90.73% less than in 2024.

Financial Statements

News

There is no news available yet.